Swetha Gopalakrishnan

Associate

Spoken Languages

English Tamil Hindi

Silicon Valley

+1 650 752 3351

Swetha Gopalakrishnan

Silicon Valley

+1 650 752 3351

Swetha Gopalakrishnan is an associate in Goodwin’s Business Law department and a member of its Technology and Life Sciences group. She joined Goodwin in 2022. Swetha represents private and public companies in broad range of transactions, including startup and formation, venture capital financings, mergers and acquisitions, capital market transactions, and corporate governance and securities compliance.

EXPERIENCE

Swetha’s recent representative experience, among others, includes:

Medipost Co. Ltd., in its joint venture with Centre for Commercialization of Regenerative Medicine (CCRM) for the acquisition of OmniaBio, Inc.
Greenlight Biosciences, Inc., in its take-private acquisition by a consortium led by Fall Line Endurance Fund, in an all-cash transaction of approximately $45.5 million
Graphite Bio, Inc., in its reverse merger transaction with LENZ Therapeutics, Inc., including concurrent private placement offering
Deciphera Pharmaceuticals, Inc., in its take-private acquisition by ONO Pharmaceutical Co., Ltd., for a total equity value of $2.4 billion
Human Immunology Biosciences, Inc., in its sale to Biogen Inc. for a total value of $1.15 billion
Prolaio, Inc. in its sale to Kardigan, Inc.
BridgeBio Oncology Therapeutics, Inc., in its de-SPAC transaction with Helix Acquisition Corp. II, including concurrent private placement offering

Deciphera Pharmaceuticals, Inc., in its follow-on offering of approximately $143.7 million
Senti Biosciences, Inc., in its committed equity line financing of approximately $50 million
Deciphera Pharmaceuticals, Inc., in its at-the-market (ATM) offering
PepGen Inc., in its follow-on offering of approximately $80.1 million
Vivani Medical, Inc., in its registered direct offering of approximately $15 million
Vivani Medical, Inc., in its at-the-market (ATM) offering
PepGen Inc. in its follow-on offering of approximately $115 million
Senti Biosciences, Inc., in its PIPE financing of approximately $47.5 million
CERo Therapeutics Holdings, Inc., in its follow-on offering of approximately $5 million
Vivani Medical, Inc., in its private equity financing of approximately $8.25 million
Vivani Medical, Inc., in its private equity financing of approximately $3 million

Vedanta Biosciences, Inc., in its convertible note financing'
CSA Medical, Inc., in its convertible note financings
Alltrna, Inc., in its Series B financing
ZymoChem, Inc., in its Series A financing
CSA Medical, Inc., in its Series D financing
Quotient Therapeutics, Inc., in its Series A-2 financing
Numerous other private companies and venture capital firms in connection with equity and convertible debt financings

Areas of Practice

Professional Experience

Prior to joining Goodwin, Swetha was a Legal Consultant at Chugh, LLP, where she advised clients (corporations and individuals) on business transactions and business-related litigation matters. While attending law school, she worked as a Legal and Compliance Intern at a leading global investment firm, assisting the team with regulatory compliance as well as corporate matters.

Swetha Gopalakrishnan

EXPERIENCE

Areas of Practice

Professional Experience

Credentials

Education

JD2019

BSL, LLB2016

Admissions

Bars

Related Content

Goodwin Guides Avalo Therapeutics on Pricing of $430 Million Public Offering

Bitdeer Completes $400 Million Convertible Senior Notes Offering with Capped Call and Registered Direct Offering

Goodwin Advises Ollin Biosciences in $100 Million Launch and Collaboration with Innovent Biologics to Develop OLN324

Goodwin Guides BridgeBio Oncology Therapeutics in Debut as a Publicly Traded Company

Deciphera Pharmaceuticals Completes Its Sale to ONO Pharmaceutical For $2.4 Billion

Deciphera Pharmaceuticals To Be Acquired By ONO Pharmaceutical For $2.4 Billion

Graphite Bio and LENZ Therapeutics To Merge

GreenLight Biosciences to be Acquired in a Go-Private Transaction by a Consortium Led by Fall Line Endurance Fund

Life Sciences

Technology

Mergers & Acquisitions

Venture Capital

Capital Markets

Life Sciences Emerging Companies

Swetha Gopalakrishnan

EXPERIENCE

Mergers & Acquisitions

Capital Markets

Private Financings

Areas of Practice

Professional Experience

Credentials

Education

JD2019

BSL, LLB2016

Admissions

Bars

Related Content

Goodwin Guides Avalo Therapeutics on Pricing of $430 Million Public Offering

Bitdeer Completes $400 Million Convertible Senior Notes Offering with Capped Call and Registered Direct Offering

Goodwin Advises Ollin Biosciences in $100 Million Launch and Collaboration with Innovent Biologics to Develop OLN324

Goodwin Guides BridgeBio Oncology Therapeutics in Debut as a Publicly Traded Company

Deciphera Pharmaceuticals Completes Its Sale to ONO Pharmaceutical For $2.4 Billion

Deciphera Pharmaceuticals To Be Acquired By ONO Pharmaceutical For $2.4 Billion

Graphite Bio and LENZ Therapeutics To Merge

GreenLight Biosciences to be Acquired in a Go-Private Transaction by a Consortium Led by Fall Line Endurance Fund